Evidence map›Paper›PMID 31965629›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2020

Motor complications in Parkinson's disease: 13-year follow-up of the CamPaIGN cohort.

Han-Joon Kim, Sarah Mason, Thomas Foltynie, Sophie Winder-Rhodes, Roger A Barker, Caroline H Williams-Gray

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 2 pooled it
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2022
    Trial
  7. On-demand therapies-emergency medication or daily routine?Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Refractory Motor Complications: Towards a Pragmatic Definition.Movement disorders clinical practice · 2026
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Early-Onset Parkinson's Disease: Unique Features and Management Approaches.Current neurology and neuroscience reports · 2025
    Review
  19. Interpretable Machine Learning for Cross-Cohort Prediction of Motor Fluctuations in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 3 countries.

Han-Joon KimDepartment of Neurology and Movement Disorder Center, College of Medicine, Seoul National University, Seoul, Korea.ORCID 0000-0001-8219-9663
Sarah MasonJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Thomas FoltynieDepartment of Clinical & Movement Neurosciences, UCL Queen Square Institute of Neurology, London, UK.ORCID 0000-0003-0752-1813
Sophie Winder-RhodesJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Roger A BarkerJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Caroline H Williams-GrayJohn van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
University of Cambridge · GBQueen Mary University of London · GBSeoul National University · KR

Funding

Medical Research Council MR/R007446/1Wellcome Trust
6 · The paper itself

Abstract

backgroundLong-term population-representative data on motor fluctuations and levodopa-induced dyskinesias in Parkinson's disease is lacking.

methodsThe Cambridgeshire Parkinson's Incidence from GP to Neurologist (CamPaIGN) cohort comprises incident PD cases followed for up to 13 years (n = 141). Cumulative incidence of motor fluctuations and levodopa-induced dyskinesias and risk factors were assessed using Kaplan-Meyer and Cox regression analyses.

resultsCumulative incidence of motor fluctuations and levodopa-induced dyskinesias was 54.3% and 14.5%, respectively, at 5 years and 100% and 55.7%, respectively, at 10 years. Higher baseline UPDRS-total and SNCA rs356219(A) predicted motor fluctuations, whereas higher baseline Mini-mental State Examination and GBA mutations predicted levodopa-induced dyskinesias. Early levodopa use did not predict motor complications. Both early motor fluctuations and levodopa-induced dyskinesias predicted reduced mortality in older patients (age at diagnosis >70 years).

conclusionsOur data support the hypothesis that motor complications are related to the severity of nigrostriatal pathology rather than early levodopa use and indicate that early motor complications do not necessarily confer a negative prognosis. © 2019 International Parkinson and Movement Disorder Society.

Indexed as

AdultAntiparkinson AgentsDyskinesia, Drug-InducedFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedMotor ActivityParkinson DiseaseRegression AnalysisRetrospective StudiesRisk FactorsAntiparkinson Agentslevodopa-induced dyskinesiasmotor complicationsmotor fluctuationsParkinson's disease

Identifiers

PMID31965629
PMCPMC7063985
OpenAlexW2972743175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.